Why Palisade Bio, Inc.’s (PALI) Stock Is Down 5.20%
As of Wednesday, July 29, Palisade Bio, Inc.’s PALI share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Commentary & Analysis
Why Palisade Bio, Inc.’s (PALI) Stock Is Up 10.26%
As of Thursday, July 23, Palisade Bio, Inc.’s PALI share price has surged by 10.26%, which has investors questioning if this is right time to sell.Michael Rose
Why Palisade Bio, Inc.’s (PALI) Stock Is Up 12.37%
As of Thursday, July 23, Palisade Bio, Inc.’s PALI share price has surged by 12.37%, which has investors questioning if this is right time to sell.Tudor Pop
Why Palisade Bio, Inc.’s (PALI) Stock Is Up 5.56%
As of Friday, July 17, Palisade Bio, Inc.’s PALI share price has surged by 5.56%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Palisade Bio, Inc.’s (PALI) Stock Is Down 5.37%
As of Thursday, July 09, Palisade Bio, Inc.’s PALI share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PALI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $338.5 | $251.9 | 33% |
|
| Shares Out (Mil) | 209.7 | 50.8 | 77% |
|
| Institutional Ownership | 99.4% | 92.0% | 88% |
|
| Float (Mil) | 132.9 | 40.5 | 67% |
|
| Beta | 1.53 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 2,437 | 447 | 85% |
|
| Price Change (52-week) |
78.9% | 54.2% | 89% |
|
| Growth | PALI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (10.3%) | (9.8%) | 28% |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.053) | ($0.239) | ($0.286) | |
| Month Ago EPS | ($0.053) | ($0.239) | ($0.286) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.043) | ($0.188) | ($0.220) | |
| Year/Year Chg | 15.2% | (20.6%) | 16.9% | |
| Financials | PALI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($24) | ($43) | 22% |
|
| EPS (TTM) | ($0.226) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($30) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $192 | $182 | 26% |
|
| Valuation | PALI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.57 | 2.60 | 60% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PALI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (34.1%) | (49.7%) | 16% |
|
| ROE | (36.4%) | (55.4%) | 18% |
|
| Liabilities to Assets | 4.5% | 30.3% | 2% |
|
| F-Score | 3 | 3 | 19% |
|
Palisade Bio, Inc. did not pass any screens on 7/30/2026.
